AFFiRiS
Manufacturing · Austria · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Karl-farkas-gasse 22 2A, Vienna, Vienna,...Phone Number
+43 17981575300Website
www.affiris.comRevenue
$12.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About AFFiRiS
AFFiRiS is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for chronic diseases, particularly neurodegenerative conditions and hypercholesterolemia. Utilizing their proprietary AFFITOME technology, they aim to create Specific Active Immunotherapies (SAIT) that stimulate the immune system to combat disease progression. The company is dedicated to addressing unmet medical needs by providing therapies that improve the quality of life for patients. Their innovative approach seeks to offer more effective treatment options with less frequent dosing regimens.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AFFiRiS your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on AFFiRiS recently announced quarterly report
AFFiRiS, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when AFFiRiS launches new products
Check if AFFiRiS has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at AFFiRiS
Check out if AFFiRiS is spiking on competitors!
Funding: Get notified immidiatlly once AFFiRiS has new funding data
Click to see if AFFiRiS had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at AFFiRiS
Find more new buyers
Company Profile Activity
Activity Insights
AFFiRiS is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AFFiRiS is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AFFiRiS.
AFFiRiS financials insights
Gather financial insights about AFFiRiS, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Other Financing Round
$33.9M
2016
Private Equity
$11.3M
Other Financing Round
$10M
2017
Other Financing Round
$10.9M
AFFiRiS Tech Stack
A closer look at the technologies used by AFFiRiS
See more technologies
AFFiRiS News & Media
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS’ anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteAFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
VIENNA, Austria, May 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that detailed results of a large phase 1 clinical study with two of its AFFITOPE® peptide vaccine candidates in the cardiovascular disease indication hypercholesterolemia were published in the peer-reviewed journal European Journal of Clinical Pharmacology (https://doi.org/10.1007/s00228-021-03149-2). The
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AFFiRiS
Sign Up For FreeTo access detailed company insights
AFFiRiS is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for chronic diseases, particularly neurodegenerative conditions and hypercholesterolemia. Utilizing their proprietary AFFITOME technology, they aim to create Specific Active Immunotherapies (SAIT) that stimulate the immune system to combat disease prog... Read More
